Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol
Miriam Dixon-Zegeye(University of Oxford), Sarah P. Blagden(Churchill Hospital), Pan Pantziarka, Rachel Shaw(University of Oxford), Helen Hanson(University of Exeter), Emma R. Woodward(Royal Manchester Children's Hospital), Louise Izatt(Guy's and St Thomas' NHS Foundation Trust), Alexander Ooms(Nuffield Orthopaedic Centre), James Franklin(Nottingham University Hospitals NHS Trust), Marc Tischkowitz(University of Cambridge), Linda M. Collins(Human Growth Foundation), Simon Lord(University of Oxford), D. Gareth Evans(Manchester Academic Health Science Centre), Kendra Perez-Smith(University of Oxford), Maggie Qiao(Nuffield Orthopaedic Centre), Lara Hawkes(Oxford University Hospitals NHS Trust), Rachel E. Harrison(Nottingham University Hospitals NHS Trust), Angela George(Royal Marsden NHS Foundation Trust)
Cited by 15
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2
|Nature Genetics|2009|484